Pipeline >> SP-333

»

SP-333

SP-333 lead drug: GC-C Receptor Agonist

SP-333

A second-generation Synergy drug candidate that targets GC-C receptors in the GI tract, and is in preclinical development to treat GI diseases.

  1. ✓“Second-generation” drug positioned for ulcerative colitis (UC)

  2. ✓IND planned for 2012

  3. ✓First trial in healthy volunteers to test for systemic absorption

About UsAbout_Synergy_Pharmaceuticals.htmlshapeimage_8_link_0
PipelinePipeline_Overview.htmlshapeimage_9_link_0
PartneringPartnering.htmlshapeimage_10_link_0
Investor RelationsInvestor_Relations_Information.htmlshapeimage_11_link_0
NewsSynergy_News_Summary.htmlshapeimage_12_link_0
Contact UsContact_Us.htmlshapeimage_13_link_0
Pipeline OverviewPipeline_Overview.htmlshapeimage_15_link_0
SP-304Plecanatide_SP-304.htmlPlecanatide_SP-304.htmlshapeimage_16_link_0shapeimage_16_link_1
SP-333shapeimage_17_link_0
Synergy Clinical TrialsSynergy_Clinical_Trials.htmlshapeimage_18_link_0
Basic ScienceBasic_Science.htmlshapeimage_19_link_0
MarketsMarkets.htmlshapeimage_20_link_0
Publications & PresentationsPublications_Presentations.htmlshapeimage_21_link_0
Legal | Contact UsLegal.htmlContact_Us.htmlshapeimage_23_link_0shapeimage_23_link_1
Copyright 2010 © Synergy Pharmaceuticals, Inc., 420 Lexington Avenue, Suite 1609, New York, NY 10170, USA